In vitro tailoring of regulatory T cells prior to cell therapy
P Baeten, N Hellings, B Broux - Trends in Molecular Medicine, 2020 - cell.com
P Baeten, N Hellings, B Broux
Trends in Molecular Medicine, 2020•cell.comIsolated regulatory T cells (Tregs) are expanded in vitro using anti-CD3/anti-CD28 beads
(activation/proliferation) and IL-2 (survival). Polyclonal Tregs are reintroduced into patients
safely in graft-versus-host disease (GvHD), transplantation rejection, and type 1 diabetes
mellitus (T1DM) clinical trials. The expansion step provides a window of opportunity for in
vitro Treg manipulation to boost their function and stability, which are impaired in
autoimmunity.
(activation/proliferation) and IL-2 (survival). Polyclonal Tregs are reintroduced into patients
safely in graft-versus-host disease (GvHD), transplantation rejection, and type 1 diabetes
mellitus (T1DM) clinical trials. The expansion step provides a window of opportunity for in
vitro Treg manipulation to boost their function and stability, which are impaired in
autoimmunity.
Isolated regulatory T cells (Tregs) are expanded in vitro using anti-CD3/anti-CD28 beads (activation/proliferation) and IL-2 (survival). Polyclonal Tregs are reintroduced into patients safely in graft-versus-host disease (GvHD), transplantation rejection, and type 1 diabetes mellitus (T1DM) clinical trials. The expansion step provides a window of opportunity for in vitro Treg manipulation to boost their function and stability, which are impaired in autoimmunity.
cell.com
